Custom cancer vaccine fights deadly eye tumor return
NCT ID NCT01983748
Summary
This study tested whether a personalized vaccine could prevent cancer from returning in patients with a high-risk form of eye melanoma (uveal melanoma) after their tumor was surgically removed. 200 patients who had their tumor removed but were at high risk for the cancer spreading were randomly assigned to either receive the vaccine or be closely monitored without it. The vaccine was made by training the patient's own immune cells with genetic material from their removed tumor, then giving these cells back as injections over two years to teach the immune system to attack any remaining cancer cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UVEAL MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dept. of Dermatology, University Hospital
Erlangen, Bavaria, 90154, Germany
-
Städtisches Klinikum
Dessau, 06847, Germany
-
University Hospital Department of Ophtalmology
Erlangen, Bavaria, 91054, Germany
-
University Hospital Department of Ophtalmology
Würzburg, Bavaria, 97080, Germany
-
University Hospital Department of Ophtalmology
Essen, 45122, Germany
-
University Hospital Department of Ophtalmology
Homburg/Saar, 66421, Germany
-
University Hospital Department of Ophtalmology
Lübeck, 23538, Germany
-
University Hospital Department of Ophtalmology
Tübingen, 72076, Germany
Conditions
Explore the condition pages connected to this study.